Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 93Recruiting 37Unknown 26Active not recruiting 14Terminated 6Not yet recruiting 6Withdrawn 4Enrolling by invitation 3

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Breast Neoplasms 58Neoplasms 52Colorectal Neoplasms 32Prostatic Neoplasms 29Lung Neoplasms 21Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 16Uterine Cervical Neoplasms 13Anxiety Disorders 13Colonic Neoplasms 11Brain Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Follicular 9Leukemia, Myeloid, Acute 8Head and Neck Neoplasms 8Barrett Esophagus 8Urinary Bladder Neoplasms 7Rectal Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Disease 7Diabetes Mellitus 7Cholangiocarcinoma 7Sarcoma 6Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Pain 6Ovarian Neoplasms 6Motor Activity 6

Interventions

7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Enrolling by invitation × OTHER × Cognitive Dysfunction × Clear all
NCT06723015 2025-11-18

Tau PET Outcomes With Anti-amyloid Immunotherapies

Mayo Clinic

Phase 2 Enrolling by invitation
135 enrolled
Lymphoid

Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT02670161 2025-08-24

Quality Improvement and Practice Based Research in Neurology Using the EMR

Endeavor Health

Phase 4 Enrolling by invitation
3,300 enrolled
CNS

Brain Concussion, Brain Neoplasms, Epilepsy, Migraine Disorders, Multiple Sclerosis, Parkinson Disease, Restless Legs Syndrome, Stroke, Cognitive Dysfunction

NCT06950190 2025-08-12

(ECCPC)

Ellis Medicine

Phase 3 Enrolling by invitation
100 enrolled

Chemotherapy-Related Cognitive Impairment, Neurotoxicity Syndromes, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡